Literature DB >> 26959385

Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer.

A Blythe Ryerson1, Christie R Eheman1, Sean F Altekruse2, John W Ward3, Ahmedin Jemal4, Recinda L Sherman5, S Jane Henley1, Deborah Holtzman3, Andrew Lake6, Anne-Michelle Noone2, Robert N Anderson7, Jiemin Ma4, Kathleen N Ly3, Kathleen A Cronin2, Lynne Penberthy2, Betsy A Kohler5.   

Abstract

BACKGROUND: Annual updates on cancer occurrence and trends in the United States are provided through an ongoing collaboration among the American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR). This annual report highlights the increasing burden of liver and intrahepatic bile duct (liver) cancers.
METHODS: Cancer incidence data were obtained from the CDC, NCI, and NAACCR; data about cancer deaths were obtained from the CDC's National Center for Health Statistics (NCHS). Annual percent changes in incidence and death rates (age-adjusted to the 2000 US Standard Population) for all cancers combined and for the leading cancers among men and women were estimated by joinpoint analysis of long-term trends (incidence for 1992-2012 and mortality for 1975-2012) and short-term trends (2008-2012). In-depth analysis of liver cancer incidence included an age-period-cohort analysis and an incidence-based estimation of person-years of life lost because of the disease. By using NCHS multiple causes of death data, hepatitis C virus (HCV) and liver cancer-associated death rates were examined from 1999 through 2013.
RESULTS: Among men and women of all major racial and ethnic groups, death rates continued to decline for all cancers combined and for most cancer sites; the overall cancer death rate (for both sexes combined) decreased by 1.5% per year from 2003 to 2012. Overall, incidence rates decreased among men and remained stable among women from 2003 to 2012. Among both men and women, deaths from liver cancer increased at the highest rate of all cancer sites, and liver cancer incidence rates increased sharply, second only to thyroid cancer. Men had more than twice the incidence rate of liver cancer than women, and rates increased with age for both sexes. Among non-Hispanic (NH) white, NH black, and Hispanic men and women, liver cancer incidence rates were higher for persons born after the 1938 to 1947 birth cohort. In contrast, there was a minimal birth cohort effect for NH Asian and Pacific Islanders (APIs). NH black men and Hispanic men had the lowest median age at death (60 and 62 years, respectively) and the highest average person-years of life lost per death (21 and 20 years, respectively) from liver cancer. HCV and liver cancer-associated death rates were highest among decedents who were born during 1945 through 1965.
CONCLUSIONS: Overall, cancer incidence and mortality declined among men; and, although cancer incidence was stable among women, mortality declined. The burden of liver cancer is growing and is not equally distributed throughout the population. Efforts to vaccinate populations that are vulnerable to hepatitis B virus (HBV) infection and to identify and treat those living with HCV or HBV infection, metabolic conditions, alcoholic liver disease, or other causes of cirrhosis can be effective in reducing the incidence and mortality of liver cancer. Cancer 2016;122:1312-1337.
© 2016 American Cancer Society. © 2016 American Cancer Society.

Entities:  

Keywords:  Epidemiology; National Program of Cancer Registries (NPCR); North American Association of Central Cancer Registries (NAACCR); Surveillance; and End Results (SEER); cancer; incidence; liver cancer; mortality; survival; trends; viral hepatitis

Mesh:

Year:  2016        PMID: 26959385      PMCID: PMC4840031          DOI: 10.1002/cncr.29936

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  104 in total

1.  The validity of race and Hispanic origin reporting on death certificates in the United States.

Authors:  Elizabeth Arias; William S Schauman; Karl Eschbach; Paul D Sorlie; Eric Backlund
Journal:  Vital Health Stat 2       Date:  2008-10

Review 2.  Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy.

Authors:  Ching-Lung Lai; Man-Fung Yuen
Journal:  Hepatology       Date:  2013-01       Impact factor: 17.425

3.  Impact of reporting delay and reporting error on cancer incidence rates and trends.

Authors:  Limin X Clegg; Eric J Feuer; Douglas N Midthune; Michael P Fay; Benjamin F Hankey
Journal:  J Natl Cancer Inst       Date:  2002-10-16       Impact factor: 13.506

4.  Prevalence of chronic hepatitis B virus (HBV) infection in U.S. households: National Health and Nutrition Examination Survey (NHANES), 1988-2012.

Authors:  Henry Roberts; Deanna Kruszon-Moran; Kathleen N Ly; Elizabeth Hughes; Kashif Iqbal; Ruth B Jiles; Scott D Holmberg
Journal:  Hepatology       Date:  2015-10-27       Impact factor: 17.425

5.  Sofosbuvir for previously untreated chronic hepatitis C infection.

Authors:  Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane
Journal:  N Engl J Med       Date:  2013-04-23       Impact factor: 91.245

6.  Causes of death and characteristics of decedents with viral hepatitis, United States, 2010.

Authors:  Kathleen N Ly; Jian Xing; R Monina Klevens; Ruth B Jiles; Scott D Holmberg
Journal:  Clin Infect Dis       Date:  2013-09-24       Impact factor: 9.079

7.  Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer.

Authors:  Brenda K Edwards; Anne-Michelle Noone; Angela B Mariotto; Edgar P Simard; Francis P Boscoe; S Jane Henley; Ahmedin Jemal; Hyunsoon Cho; Robert N Anderson; Betsy A Kohler; Christie R Eheman; Elizabeth M Ward
Journal:  Cancer       Date:  2013-12-16       Impact factor: 6.860

8.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

Authors:  Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen
Journal:  JAMA       Date:  2012-12-26       Impact factor: 56.272

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Authors:  Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

View more
  375 in total

1.  Benefits of marriage on relative and conditional relative cancer survival differ between males and females in the USA.

Authors:  Ray M Merrill; Erin Johnson
Journal:  J Cancer Surviv       Date:  2017-08-02       Impact factor: 4.442

Review 2.  Promising practices for the prevention of liver cancer: a review of the literature and cancer plan activities in the National Comprehensive Cancer Control Program.

Authors:  Behnoosh Momin; Alexander J Millman; Danielle Beauchesne Nielsen; Michelle Revels; C Brooke Steele
Journal:  Cancer Causes Control       Date:  2018-12-01       Impact factor: 2.506

3.  Dietary Patterns and Risk of Hepatocellular Carcinoma Among U.S. Men and Women.

Authors:  Yanan Ma; Wanshui Yang; Tracey G Simon; Stephanie A Smith-Warner; Teresa T Fung; Jing Sui; Dawn Chong; Trang VoPham; Jeffrey A Meyerhardt; Deliang Wen; Edward L Giovannucci; Andrew T Chan; Xuehong Zhang
Journal:  Hepatology       Date:  2019-03-05       Impact factor: 17.425

Review 4.  The Effects of Physical Exercise on Fatty Liver Disease.

Authors:  Dirk J van der Windt; Vikas Sud; Hongji Zhang; Allan Tsung; Hai Huang
Journal:  Gene Expr       Date:  2017-12-06

5.  A Comparison of Open and Minimally Invasive Surgery for Hepatic and Pancreatic Resections Among the Medicare Population.

Authors:  Qinyu Chen; Katiuscha Merath; Fabio Bagante; Ozgur Akgul; Mary Dillhoff; Jordan Cloyd; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2018-07-23       Impact factor: 3.452

6.  Incidence of primary liver cancer in American Indians and Alaska Natives, US, 1999-2009.

Authors:  Stephanie C Melkonian; Melissa A Jim; Brigg Reilley; Jennifer Erdrich; Zahava Berkowitz; Charles L Wiggins; Donald Haverkamp; Mary C White
Journal:  Cancer Causes Control       Date:  2018-07-20       Impact factor: 2.506

7.  Using Inside Knowledge Campaign Materials to Improve Gynecologic Cancer Knowledge in Underserved Women.

Authors:  Mary Puckett; Julie Townsend; Jenny Rees Patterson; Donna Shaw; Yvonne Wasilewski; Sherri L Stewart
Journal:  J Womens Health (Larchmt)       Date:  2019-08-02       Impact factor: 2.681

8.  Trends in liver cancer mortality in the United States: Dual burden among foreign- and US-born persons.

Authors:  Meheret Endeshaw; Benjamin D Hallowell; Hilda Razzaghi; Virginia Senkomago; Matthew T McKenna; Mona Saraiya
Journal:  Cancer       Date:  2018-11-27       Impact factor: 6.860

9.  Application of propofol combined with sevoflurane anesthesia in staged hepatectomy liver detachment and portal vein ligation.

Authors:  Fei Xu; Hongbo Jiang; Meishan Jin; Qihua Peng
Journal:  Exp Ther Med       Date:  2021-06-30       Impact factor: 2.447

10.  Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease.

Authors:  Fasiha Kanwal; Jennifer R Kramer; Srikar Mapakshi; Yamini Natarajan; Maneerat Chayanupatkul; Peter A Richardson; Liang Li; Roxanne Desiderio; Aaron P Thrift; Steven M Asch; Jinna Chu; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2018-08-23       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.